Related Experiment Video
Updated: Jul 16, 2026
Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
Autologous stem cell transplantation for secondary central nervous system lymphoma: a multicentre retrospective
Meredith W Tan1, Victor Ling2, Jing Yuan Tan1
1Department of Haematology, Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore.
Background:
Secondary Central Nervous Lymphoma (SCNSL) is an aggressive lymphoma with poor outcomes. Consensus regarding consolidation with thiotepa-based autologous transplant (ASCT) for SCNSL is lacking.
Methods:
Our retrospective Singapore study examined survival outcomes post ASCT in 27 patients (median age 57 years) with SCNSL in two tertiary cancer centres from 2013 to 2024.
Results:
Five (18.5%) patients had de novo SCNSL, 14 (51.9%) patients had isolated CNS relapsed SCNSL and 8 (29.6%) patients had synchronous relapsed SCNSL. At the time of ASCT, 16 (59.3%), 7 (25.9%) and 4 (14.8%) patients were in CR, PR and SD/PD respectively. Median follow up for the 22 relapsed SCNSL patients was 63 (5-109) months with a median PFS and OS of 11.5 and 30 months, respectively, and 4-year PFS and OS rates of 35.0% and 48.0%, respectively. In our analysis, females demonstrated superior median and 4-year PFS and OS compared to males, likely related to difference in age and performance status. On multivariate analysis, CR/PR at time of ASCT trended toward an improved OS (HR 7.86, p = 0.06) although this was not statistically significant.
Conclusion:
Our data suggests that in secondary CNSL, chemo-sensitivity would likely confer good outcomes with thiotepa-based consolidation ASCT. Conversely, patients responding poorly to salvage chemotherapy may consider alternatives including CAR-T cell therapy.
